A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
A Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Trial to Evaluate, Tolerability, and Immunogenicity of V540D in Healthy Adults.
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT06688058, this PHASE1 trial focuses on Healthy and remains ongoing. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2025 — Mar 2026 [monthly]
Recruiting PHASE1
-
Aug 2025 — Nov 2025 [monthly]
Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
Feb 2025 — May 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .